公开(公告)号：US20190022090A1

公开(公告)日：2019-01-24

申请号：US16054667

申请日：2018-08-03

Applicant: Unity Biotechnology, Inc. ,  Buck Institute for Research on Aging ,  Mayo Foundation for Medical Education and Research

Inventor： Remi-Martin Laberge ,  Judith Campisi ,  Marco Demaria ,  Nathaniel David ,  Alain Philippe Vasserot ,  James L. Kirkland ,  Tamar Tchkonia ,  Yi Zhu ,  Darren J. Baker ,  Bennett G. Childs ,  Jan M.A. van Deursen

IPC: A61K31/496 ,  A61K9/00 ,  A61K31/428 ,  A61K47/36 ,  C12N5/00 ,  A61K31/728 ,  A61K31/4178 ,  A61K45/06 ,  A61K31/4375 ,  A61K31/404 ,  A61K31/5377 ,  A61K31/495

CPC classification number: A61K31/496 ,  A61K9/0048 ,  A61K9/0073 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  A61P9/10 ,  A61P11/00 ,  A61P27/02 ,  C12N5/0081 ,  C12N2501/999 ,  C12N2503/02 ,  C12Q1/485

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

公开(公告)号：US20190000846A1

公开(公告)日：2019-01-03

申请号：US16025238

申请日：2018-07-02

Applicant: Mayo Foundation for Medical Education and Research ,  Buck Institute for Research on Aging ,  Unity Biotechnology, Inc.

Inventor： Jan M.A. van Deursen ,  Bennett G. Childs ,  Darren J. Baker ,  James L. Kirkland ,  Tamar Tchkonia ,  Yi Zhu ,  Nathaniel David ,  Remi-Martin Laberge ,  Judith Campisi ,  Marco Demaria

IPC: A61K31/506 ,  A61P9/14 ,  A61K31/40 ,  A61K31/22

Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. This invention provides senolytic agents that remove senescent cells that are present in or around atherosclerotic plaques. The agents inhibit or reverse thinning of the fibrous cap on atherosclerotic plaques. This has the effect of stabilizing the plaques, inhibiting rupture and preventing pathological sequelae that manifest as coronary artery disease. Senolytic agents used in this way complement the action of statins and other drugs that cause plaque regression. Thus, senolytic agents and lipid lowering drugs can be used in combination for enhanced therapeutic effect.

公开(公告)号：US10130628B2

公开(公告)日：2018-11-20

申请号：US15481129

申请日：2017-04-06

Applicant: Unity Biotechnology, Inc. ,  Buck Institute for Research on Aging ,  The Johns Hopkins University ,  Mayo Foundation for Medical Education and Research

Inventor： Nathaniel David ,  Albert Davalos ,  Remi-Martin Laberge ,  Judith Campisi ,  Marco Demaria ,  Alain Vasserot ,  Chaekyu Kim ,  Okhee Jeon ,  Jennifer Elisseeff ,  James L. Kirkland ,  Tamar Tchkonia ,  Yi Zhu

IPC: A61K31/496 ,  A61K31/495 ,  A61K31/404 ,  A61K31/4375 ,  A61K31/428 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/4178 ,  A61K31/728 ,  C12N5/00 ,  A61K47/36 ,  A61K9/00

Abstract: This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).

公开(公告)号：US20180303828A1

公开(公告)日：2018-10-25

申请号：US16007880

申请日：2018-06-13

Applicant: Unity Biotechnology, Inc. ,  Buck Institute for Research on Aging ,  Mayo Foundation for Medical Education and Research

Inventor： Remi-Martin Laberge ,  Judith Campisi ,  Marco Demaria ,  Nathaniel David ,  Darren J. Baker ,  James L. Kirkland ,  Tamar Tchkonia ,  Yi Zhu ,  Jan M.A. van Deursen

IPC: A61K31/496 ,  A61K31/428 ,  A61K45/06 ,  A61K31/495 ,  A61K31/5377 ,  A61K9/00 ,  A61K31/404 ,  A61K31/4375

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

公开(公告)号：US20180235956A1

公开(公告)日：2018-08-23

申请号：US15955542

申请日：2018-04-17

Applicant: Buck Institute for Research on Aging ,  Unity Biotechnology, Inc. ,  Mayo Foundation for Medical Education and Research

Inventor： Remi-Martin Laberge ,  Judith Campisi ,  Marco Demaria ,  Nathaniel David ,  Darren J. Baker ,  James L. Kirkland ,  Tamar Tchkonia ,  Yi Zhu ,  Jan M.A. van Deursen

IPC: A61K31/496 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/495 ,  A61K9/00 ,  A61K31/428 ,  A61K31/404 ,  A61K31/4375

CPC classification number: A61K31/496 ,  A61K9/0048 ,  A61K9/0073 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  A61P11/00 ,  C12N5/0081 ,  C12N2501/999 ,  C12N2503/02

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

公开(公告)号：US20180193458A1

公开(公告)日：2018-07-12

申请号：US15742458

申请日：2016-07-08

Applicant: Unity Biotechnology, Inc. ,  Buck Institute for Research on Aging ,  Mayo Foundation for Medical Education and Research

Inventor： Jose Alberto Lopez-Dominguez ,  Remi-Martin Laberge ,  Judith Campisi ,  Albert Davalos ,  Marco Demaria ,  Nathaniel David ,  Alain Philippe Vasserot ,  Darren J. Baker ,  Bennett G. Childs ,  James L. Kirkland ,  Tamar Tchkonia ,  Jan M.A. van Deursen ,  Yi Zhu

IPC: A61K45/06 ,  A61K31/407 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/496 ,  C07K14/47 ,  A61P35/00 ,  A61P9/10

CPC classification number: A61K45/06 ,  A01K2227/105 ,  A01K2267/0375 ,  A61K31/40 ,  A61K31/4035 ,  A61K31/407 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/635 ,  A61P9/10 ,  A61P35/00 ,  C07K14/4747 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/531 ,  A61K2300/00

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.

公开(公告)号：US20170224680A2

公开(公告)日：2017-08-10

申请号：US15114762

申请日：2015-01-28

Applicant: Buck Institute for Research on Aging ,  Unity Biotechnology, Inc. ,  Mayo Foundation for Medical Education and Research ,  The Johns Hopkins University

Inventor： Remi-Martin Laberge ,  Judith Campisi ,  Albert Davalos ,  Marco Demaria ,  Nathaniel David ,  Alain Philippe Vasserot ,  Darren J. Baker ,  Bennett G. Childs ,  James L. Kirkland ,  Tamar Tchkonia ,  Jan M.A. van Deursen ,  Jennifer Elisseeff ,  Chaekyu Kim ,  Okhee Jeon ,  Allyson K. Palmer

IPC: A61K31/496 ,  A61K45/06 ,  A61K31/428 ,  A61K31/404 ,  A61K31/4375 ,  A61K31/5377

CPC classification number: A61K31/496 ,  A61K9/0048 ,  A61K9/0073 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  C12N5/0081 ,  C12N2501/999 ,  C12N2503/02

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

公开(公告)号：US20170196857A1

公开(公告)日：2017-07-13

申请号：US15455575

申请日：2017-03-10

Applicant: Buck Institute for Research on Aging ,  Unity Biotechnology, Inc. ,  Mayo Foundation for Medical Education and Research ,  The John Hopkins University

Inventor： Remi-Martin Laberge ,  Judith Campisi ,  Albert Davalos ,  Marco Demaria ,  Nathaniel David ,  Alain Philippe Vasserot ,  Darren J. Baker ,  Bennett G. Childs ,  James L. Kirkland ,  Tamar Tchkonia ,  Jan M.A. van Deursen ,  Jennifer Elisseeff ,  Chaekyu Kim ,  Okhee Jeon ,  Allyson K. Palmer

IPC: A61K31/496 ,  A61K31/728

CPC classification number: A61K31/496 ,  A61K9/0048 ,  A61K9/0073 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  C12N5/0081 ,  C12N2501/999 ,  C12N2503/02

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

公开(公告)号：US20160339019A1

公开(公告)日：2016-11-24

申请号：US15114762

申请日：2015-01-28

Applicant: BUCK INSTITUTE FOR RESEARCH ON AGING ,  UNITY BIOTECHNOLOGY, INC. ,  MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH ,  The Johns Hopkins University

Inventor： Remi-Martin Laberge ,  Judith Campisi ,  Albert Davalos ,  Marco Demaria ,  Nathaniel David ,  Alain Philippe Vasserot ,  Darren J. Baker ,  Bennett G. Childs ,  James L. Kirkland ,  Tamar Tchkonia ,  Jan M.A. van Deursen ,  Jennifer Elisseeff ,  Chaekyu Kim ,  Okhee Jeon

IPC: A61K31/496 ,  A61K45/06 ,  A61K31/428 ,  A61K31/404 ,  A61K31/4375 ,  A61K31/5377

CPC classification number: A61K31/496 ,  A61K9/0048 ,  A61K9/0073 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  C12N5/0081 ,  C12N2501/999 ,  C12N2503/02

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Abstract translation: 本文提供了用于选择性地杀死衰老细胞并通过施用分解剂来治疗衰老相关疾病和病症的方法。 通过使用本文所述的解毒剂治疗的衰老相关疾病和病症包括与动脉硬化相关或由动脉硬化引起的心血管疾病和障碍，例如动脉粥样硬化; 特发性肺纤维化; 慢性阻塞性肺疾病; 骨关节炎 衰老相关的眼科疾病和病症; 和衰老相关的皮肤病和疾病。

公开(公告)号：US11963957B2

公开(公告)日：2024-04-23

申请号：US17114376

申请日：2020-12-07

Applicant: Buck Institute for Research on Aging ,  Unity Biotechnology, Inc. ,  Mayo Foundation for Medical Education and Research

Inventor： Remi-Martin Laberge ,  Judith Campisi ,  Albert Davalos ,  Marco Demaria ,  Nathaniel David ,  Jan M. A. van Deursen ,  Darren J. Baker ,  Bennett G. Childs

IPC: A61P9/10 ,  A61K9/00 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  A61K47/68 ,  A61P11/00 ,  A61P25/28 ,  A61P27/02 ,  C12N5/00 ,  C12N15/113 ,  C12Q1/48

CPC classification number: A61K31/496 ,  A61K9/0048 ,  A61K9/0073 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4375 ,  A61K31/495 ,  A61K31/5377 ,  A61K31/728 ,  A61K45/06 ,  A61K47/36 ,  A61K47/6807 ,  A61P9/10 ,  A61P11/00 ,  A61P25/28 ,  A61P27/02 ,  C12N5/0081 ,  C12N15/113 ,  C12N2320/30 ,  C12N2501/999 ,  C12N2503/02 ,  C12Q1/485

Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.